Treatment Response with Ca-125 in Ovarian Cancer Patients: Comparison among RECIST, WHO, Tridimensional and 3D Volumetric Criteria

被引：0
|
作者：
Oliveira, G. [1 ]
Zondervan, R. [2 ]
Harris, G. [2 ]
Hodge, S. [2 ]
Harisinghani, M. [2 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
AMERICAN JOURNAL OF ROENTGENOLOGY | 2009年 / 192卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] CA-125 criteria for response evaluation in ovarian cancer
    Sundar, S
    O'byrne, KJ
    GYNECOLOGIC ONCOLOGY, 2005, 98 (03) : 520 - 521
  • [2] Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel
    Bridgewater, JA
    Nelstrop, AE
    Rustin, GJS
    Gore, ME
    McGuire, WP
    Hoskins, WJ
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 501 - 508
  • [3] CA-125 as response criterion in patients with epithelial ovarian cancer
    Zirpel, I
    Illiger, HJ
    STRAHLENTHERAPIE UND ONKOLOGIE, 2000, 176 (04) : 200 - 200
  • [4] CA-125 IN MONITORING CHEMOTHERAPY OF PATIENTS WITH OVARIAN-CANCER - EARLY RESPONSE TO THE TREATMENT
    MARKOWSKA, J
    KOPCZYNSKI, Z
    MANYS, G
    SZEWIERSKI, Z
    NEOPLASMA, 1990, 37 (06) : 687 - 692
  • [5] Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study
    Herzog, Thomas J.
    Vermorken, Jan B.
    Pujade-Lauraine, Eric
    Provencher, Diane M.
    Jagiello-Gruszfeld, Agnieszka
    Kong, Beihua
    Boman, Karin
    Park, Youn Choi
    Parekh, Trilok
    Lebedinsky, Claudia
    Gomez, Javier
    Monk, Bradley J.
    GYNECOLOGIC ONCOLOGY, 2011, 122 (02) : 350 - 355
  • [6] Different disease progression patterns based on RECIST and CA-125 criteria and the impact on prognosis in patients with ovarian cancer treated with PARP inhibitors.
    Song, Kun
    Ma, Yana
    Bu, Hualei
    Zhang, Yawen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Differences in clinical features between CA-125 and RECIST progression in patients with ovarian cancer treated with PARP inhibitors
    Ma, Yana
    Lv, Weiwei
    Bu, Hualei
    Kong, Beihua
    Song, Kun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
    Gronlund, B
    Hogdall, C
    Hilden, J
    Engelholm, SA
    Hogdall, EVS
    Hansen, HH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (20) : 4051 - 4058
  • [9] CA-72.4 SERUM CONCENTRATIONS IN COMPARISON WITH CA-125 IN PATIENTS WITH OVARIAN-CANCER
    JAGER, W
    ADAM, R
    ONKOLOGIE, 1989, 12 (04): : 164 - 166
  • [10] VOLUMETRIC ANALYSIS COMPARING 3D QUANTIFICATION VERSUS RECIST AND WHO CRITERIA IN PATIENT WITH BRAIN METASTASES
    Bourque, J. -M.
    Wilson, L.
    Parraga, G.
    Bauman, G.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S35 - S36
12345